Human Papillomavirus (HPV) Vaccine Market Research Report and Outlook by 2028

The global market for the human papillomavirus (HPV) vaccine was valued at approximately US$ 4,273.84 million in 2022 and is anticipated to grow to US$ 5,730.50 million by 2028, reflecting a compound annual growth rate (CAGR) of 5.0% during the period from 2022 to 2028.

The expansion of the HPV vaccine market can be primarily attributed to the rising incidence of HPV-related diseases and the increasing initiatives undertaken by international health organizations. Nevertheless, the high cost associated with HPV vaccines poses a significant barrier to market growth.

Healthcare organizations have implemented various strategies aimed at preventing and eradicating HPV infections. In August 2020, the World Health Assembly endorsed a global strategy for the elimination of cervical cancer. This strategy mandates that all countries strive to maintain an incidence rate of cervical cancer below four per 100,000 women. To achieve this goal, nations are encouraged to prioritize vaccination, screening, and treatment for cervical cancer.

In 2014, the American Cancer Society, in collaboration with the Centers for Disease Control and Prevention (CDC), launched the National HPV Vaccination Roundtable, which is focused on decreasing the incidence and mortality rates of HPV-related cancers in the United States. Additionally, the American Cancer Society's initiative, Mission: HPV Cancer Free, aims to eliminate vaccine-preventable HPV cancers, particularly cervical cancer, as a public health concern. The initiative seeks to achieve an annual vaccination rate of 80% among 13-year-olds in the U.S. by 2026.

In 2016, the Gavi Board initiated a program for HPV vaccination, enabling countries to vaccinate girls aged 9 to 14 years in their first year of participation. This initiative aimed to protect around 40 million girls from cervical cancer by 2020, potentially preventing approximately 900,000 deaths. A total of 27 countries accepted Gavi's support and incorporated the HPV vaccine into their national immunization programs. Countries with the highest cervical cancer burdens, including Malawi, Tanzania, Uganda, Zambia, and Zimbabwe, have implemented the Gavi HPV vaccine program, significantly contributing to the global HPV vaccine market's growth.

The COVID-19 pandemic has had lasting effects on the HPV vaccine market. Many primary care clinics in the U.S. have operated at reduced capacity to comply with social distancing guidelines and stringent cleaning protocols. This reduction in in-person visits has limited opportunities for healthcare providers to discuss and administer vaccines. Transportation barriers have also negatively impacted HPV vaccination efforts, as pharmaceutical and biotech companies face challenges in promoting vaccines due to parental resistance and a lack of awareness regarding school entry requirements for other adolescent vaccines. Evidence indicates that the pandemic severely disrupted HPV vaccine delivery in 2020 and 2021, with CDC reports showing a more than 70% drop in ordering and billing in March 2020. Furthermore, a 25-50% decline in HPV vaccine orders persisted into June 2020, contrasting with the recovery of early childhood vaccine orders to near pre-pandemic levels. Although the HPV vaccine market is gradually recovering, data suggest a significant short-term decline in vaccination coverage, with long-term demand for HPV vaccines expected to increase in North America.

In Europe, the COVID-19 pandemic placed unprecedented pressure on health systems and disrupted routine vaccination programs, highlighting the need for resilient and sustainable immunization strategies. The global crisis also affected HPV vaccination initiatives. School closures prevented students from attending classes, and uncertainties related to the pandemic disrupted operations in the education sector, leading to delays in administering school-based vaccines. For instance, the Hellenic Pediatric Society in Greece reported a 45% decrease in HPV vaccine doses administered to pupils aged 11-16 in 2020. This situation emphasizes the necessity of maintaining routine immunization and recovering coverage rates. The ambitious Beating Cancer Plan of Europe aims to vaccinate at least 90% of girls and a significantly higher number of boys by 2030 with the HPV vaccine. Following a decline in COVID-19 cases in Europe, HPV vaccination rates began to rise after June 2021, as spring and summer are peak seasons for HPV infections.

The pandemic has profoundly affected the HPV vaccine market, with vaccination programs experiencing severe disruptions. Globally, 872 million students were unable to attend school due to closures, delaying the delivery and administration of essential school-based vaccinations.

The HPV vaccine market is categorized by type into the 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment held the largest market share, while the 9-valent HPV vaccine segment is projected to experience rapid growth from 2022 to 2028. The 9-valent HPV vaccine offers enhanced protection against five additional strains (HPV types 31, 33, 45, 52, and 58) compared to the quadrivalent vaccine, making it a safer option.

In terms of dosage, the HPV vaccine market is divided into 2-dose and 3-dose segments. The 2-dose segment accounted for a larger market share in 2022, but the 3-dose segment is expected to register a higher CAGR during the forecast period.

By age group, the HPV vaccine market is segmented into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held a larger market share in 2022 and is anticipated to grow at a higher CAGR in the coming years.

In terms of application, the market is divided into segments for HPV-attributable cancers and genital warts. The HPV-attributable cancers segment held a larger market share in 2022 and is expected to grow at a higher CAGR during the forecast period.

Regarding distribution channels, the HPV vaccine market is segmented into doctor's offices, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held the largest market share in 2022, while the school-based health centers segment is projected to experience the highest CAGR during the forecast period.

Key organizations such as the World Health Organization (WHO), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American Cancer Society, and Gavi, The Vaccine Alliance, along with the Australian Cervical Cancer Foundation (ACCF), are among the primary and secondary sources referenced in the analysis of the global HPV vaccine market.